Construction and mechanism of histone deacetylation related gene prognosis model in esophageal carcinoma

Histone deacetylases (HDACs) correlate closely with tumor prognosis and serve as therapeutic targets for malignancies. This study aimed to explore esophageal carcinoma (ESCA) therapeutic strategies via identifying histone deacetylation-related prognostic genes. We analyzed The Cancer Genome Atlas (TCGA)-ESCA and GSE53622 datasets, along with 17 histone deacetylation-related genes (HDRGs). Differentially expressed genes (DEGs1) between tumor and normal TCGA-ESCA samples were identified; DEGs2 linked to HDRGs were screened via unsupervised clustering of TCGA-ESCA tumors. Candidate genes were defined as the intersection of DEGs1 and DEGs2, followed by functional enrichment analysis and regression analyses. TCGA-ESCA samples were stratified into high-/low-risk groups, with model validation. Independent prognostic analysis, gene set enrichment analysis (GSEA), immune/gene mutation/drug sensitivity analyses, regulatory network construction, and RT-qPCR validation were performed. The intersection of 3556 DEGs1 and 1622 DEGs2 generated 694 candidates, yielding 7 prognostic genes (UNC13C, MAP7D2, SCARA5 downregulated; SLC35D3, HSPA6, IL31RA, CXCL8 upregulated in tumors). Risk score and pathologic M were independent prognostic factors for nomogram construction, with favorable predictive value. GSEA showed enrichment in pathways like ECM receptor interaction and oxidative phosphorylation; immune correlation, drug sensitivity (e.g., WH.4.023), and RT-qPCR validation of gene expression were confirmed. This study established and verified a novel HDRG-related ESCA prognostic model. The model may serve as a potential tool for risk stratification in ESCA patients and offer new perspectives for exploring the role of histone deacetylation modifications in ESCA progression. However, its clinical translational value, including guiding immunotherapy or targeted drug selection, requires further validation in large-scale prospective studies.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2026-07-18
DOI
https://doi.org/10.1038/s41598-026-62870-z
Primary Topic
Histone Deacetylase Inhibitors Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Construction and mechanism of histone deacetylation related gene prognosis model in esophageal carcinoma

Kaiyi Tao, Yao Gu, Qiqi Yang, Tianxing Ying et al.
Scientific Reports
Histone Deacetylase Inhibitors Research
article

Construction and mechanism of histone deacetylation related gene prognosis model in esophageal carcinoma

Kaiyi Tao, Yao Gu, Qiqi Yang, Tianxing Ying, Jian Zeng
article en

Abstract

Histone deacetylases (HDACs) correlate closely with tumor prognosis and serve as therapeutic targets for malignancies. This study aimed to explore esophageal carcinoma (ESCA) therapeutic strategies via identifying histone deacetylation-related prognostic genes. We analyzed The Cancer Genome Atlas (TCGA)-ESCA and GSE53622 datasets, along with 17 histone deacetylation-related genes (HDRGs). Differentially expressed genes (DEGs1) between tumor and normal TCGA-ESCA samples were identified; DEGs2 linked to HDRGs were screened via unsupervised clustering of TCGA-ESCA tumors. Candidate genes were defined as the intersection of DEGs1 and DEGs2, followed by functional enrichment analysis and regression analyses. TCGA-ESCA samples were stratified into high-/low-risk groups, with model validation. Independent prognostic analysis, gene set enrichment analysis (GSEA), immune/gene mutation/drug sensitivity analyses, regulatory network construction, and RT-qPCR validation were performed. The intersection of 3556 DEGs1 and 1622 DEGs2 generated 694 candidates, yielding 7 prognostic genes (UNC13C, MAP7D2, SCARA5 downregulated; SLC35D3, HSPA6, IL31RA, CXCL8 upregulated in tumors). Risk score and pathologic M were independent prognostic factors for nomogram construction, with favorable predictive value. GSEA showed enrichment in pathways like ECM receptor interaction and oxidative phosphorylation; immune correlation, drug sensitivity (e.g., WH.4.023), and RT-qPCR validation of gene expression were confirmed. This study established and verified a novel HDRG-related ESCA prognostic model. The model may serve as a potential tool for risk stratification in ESCA patients and offer new perspectives for exploring the role of histone deacetylation modifications in ESCA progression. However, its clinical translational value, including guiding immunotherapy or targeted drug selection, requires further validation in large-scale prospective studies.

Scientific Reports
Zhejiang Cancer Hospital (CN)
Zhejiang Cancer Hospital
Openalex Percentile: Top 14%
Histone Deacetylase Inhibitors Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Construction and mechanism of histone deacetylation related gene prognosis model in esophageal carcinoma — Kaiyi Tao, Yao Gu, et al. · Scientific Reports (2026) | TGRS Research Map | TGRS